Loading clinical trials...
Loading clinical trials...
A Multi-Cohort Phase 1b Clinical Trial of Rituximab in Combination With Immunotherapy in Untreated and Previously Treated Follicular Lymphoma
Conditions
Interventions
Rituximab
Utomilumab
+2 more
Locations
6
United States
City of Hope
Duarte, California, United States
Yale New-Haven Hospital
New Haven, Connecticut, United States
Emory University
Atlanta, Georgia, United States
University of Chicago
Chicago, Illinois, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Washington University in St. Louis
St Louis, Missouri, United States
Start Date
October 30, 2018
Primary Completion Date
July 23, 2021
Completion Date
July 30, 2023
Last Updated
February 6, 2025
NCT07545603
NCT06149286
NCT06337318
NCT05006716
NCT06026319
NCT06510361
Lead Sponsor
Dana-Farber Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions